Webinar | November 21, 2022

Vaccine Development: How 2bind Used Accelerated Stability Studies To Optimize An Antigen For HIV-Vaccine Research

Join Dr. Thomas Schubert, CEO of 2bind, as he walks through information from the Prometheus Panta that helped them select the optimal buffer for a vaccine antigen.

You’ll learn about:

  • Why 2bind required both thermal and colloidal stability information to identify the optimal buffer for antigen stability out of a 96 condition screen
  • Which stress conditions they assessed to probe the limits of antigen stability in the selected buffer, and how DLS helped them do it
  • How they further used DLS to validate epitope integrity and antibody binding to the antigen
  • How the group used a single instrument to conduct all their experiments for buffer optimization

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online

NanoTemper Technologies, Inc.